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Hypothyroidism is one of the commonest chronic
disorders in Western populations. In the United
Kingdom, the annual incidence of primary hypothyr-
oidism in women is 3.5 per 1000 and in men 0.6 per
1000.1 During 2006 12 million prescriptions for
levothyroxine (50 μg or 100 μg tablets) were dispensed
in England, equivalent to about 1.6 million people
taking long term thyroid replacement therapy, about
3% of the population.2 The management of hypothy-
roidism is generally considered straightforward and is
mostly carried out in primary care in the UK. Cross
sectional surveys of patients taking levothyroxine
have, however, shown that between 40% and 48% are
either over-treated or under-treated.3 4 Furthermore, a
small but significant proportion of patients continue to
feel unwell despite taking levothyroxine.5 This review
discusses current approaches in the management of
hypothyroidism in adults.
What are the causes of hypothyroidism?
Box 1 lists the important causes of hypothyroidism.
Thecommonest causeofhypothyroidism indeveloped
countries is autoimmune thyroiditis, which may be
associated with a goitre (Hashimoto’s thyroiditis) or,
with equal frequency, thyroid atrophy. Radioiodine
ablation or surgical thyroidectomy as treatment for
hyperthyroidismor thyroid cancer are also responsible
for important numbers of patients with hypothyroid-
ism. Less often, hypothyroidism may be drug induced
(suggesting the possibility of reversibility) or be
secondary to disorders of the pituitary or hypothala-
mus (central or secondary hypothyroidism). Congeni-
tal hypothyroidism, due either to thyroid aplasia or
hypoplasia or to defective biosynthesis of thyroid
hormones, occurs in one per 4000 live births.6 In some
parts of the world iodine deficiency remains highly
prevalent, with consequent developmental deficits and
hypothyroidism affecting infants and children.
How do patients with hypothyroidism present?
Autoimmune thyroiditis generally causes a slow failure
of thyroid hormone production, thus symptoms may
be insidious, developing over years.1 The spectrum of
presentation ranges from fatigue or mild forgetfulness
to a severe impairment of consciousness, termed
“myxoedema coma” (box 2). Advanced presentations
of hypothyroidism are rarely seen nowadays in
developed countries.
How to diagnose hypothyroidism?
Thediagnosis of primary hypothyroidism is confirmed
by an increase in the serum thyroid stimulating
hormone concentration above the upper limit of the
reference range. Adults presenting with symptomatic
hypothyroidism often have a thyroid stimulating
hormone level in excess of 10 mU/l, coupled with a
reduction in the serum free or total thyroxine
concentration below the reference range. Some adults
have less severe hypothyroidism, with a serum thyroid
stimulating hormone that is increased (typically
between 5 mU/l and 10 mU/l) but a serum thyroxine
concentration within the reference range. This is
termed subclinical hypothyroidism (also called mild
hypothyroidism) and in many patients it represents a
state of compensated or mild thyroid failure. About a
30% diurnal variation occurs in thyroid stimulating
hormone levels, with a trough around 2 00 pm and
rising during the hours of darkness. This variability is
conserved in mild hypothyroidism, sometimes giving
the impression of fluctuating disease.7 A small varia-
bility also exists between the different assays used for
measuring thyroid stimulating hormone levels and the
reference ranges quoted by different laboratories.
Serum triiodothyronine concentration is often normal
even in severe hypothyroidism and is not a helpful
investigation in this situation. If the cause is auto-
immune, circulating antibodies directed at thyroid
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peroxidase (formerly known as microsomal anti-
bodies) or thyroglobulin are detectable in more than
90% and about 70% of patients, respectively.
Whom to treat for hypothyroidism?
The figure shows a pragmatic algorithm for the
management of primary hypothyroidism in non-
pregnant adults.
Overt hypothyroidism with thyroid stimulating hormone
concentrations >10 mU/l
Symptomatic people with thyroid stimulating hor-
mone concentrations above 10 mU/l should be
treated.8 9 As treatment is likely to be life long, it is
good practice to confirm the increase in thyroid
stimulating hormone on a second sample. Adults
with symptomatic overt hypothyroidism usually feel
better with treatment. In addition, treatment may
reverse the associated dyslipidaemia, with a conse-
quent improvement in vascular risk.10 Unless the
patient has drug induced hypothyroidism (for exam-
ple, lithium, amiodarone, interferons) or is in the
recovery phase of a thyroiditis (for example, post-
partum thyroiditis or painful subacute thyroiditis),
there is little chance of spontaneous recovery from this
degree of hypothyroidism.
Subclinical (mild) hypothyroidism: thyroid stimulating
hormone between 5 and 10 mU/l (free serum thyroxine in
reference range)
Whether people with subclinical hypothyroidism
should be treated with thyroxine is controversial.
Some of these patients have symptoms of hypothy-
roidism. A 20 year follow-up study showed a small risk
of progression to overt hypothyroidism, which corre-
lates with the level of thyroid stimulating hormone and
the presence of thyroid peroxidase antibodies.1 In
addition, two recent meta-analyses have shown an
association between subclinical hypothyroidism and
cardiovascular morbidity and mortality11 12; however,
another meta-analysis failed to show a benefit of
thyroxine replacement in reducing these adverse
outcomes.13 In people aged more than 85 years,
evidence suggests that subclinical hypothyroidism is
associated with longevity.14 A recent scientific review
by an expert panel did not support the routine use of
thyroxine in subclinical hypothyroidism.9
In practice the level of thyroid stimulating hormone
should be remeasured, along with doing a test for
thyroid peroxidase antibodies, within three months of
the initial test to ascertain the persistence of the
abnormal level of thyroid stimulating hormone and
the tempo of the thyroid failure. A transient, modest
increase in hormone levels may be found during
recovery from non-thyroidal illness. If patients have
symptoms consistent with hypothyroidism and the
increase in thyroid stimulatinghormonepersists, thena
therapeutic trial of levothyroxine for three to six
months is a reasonable approach. If the patient feels
improved by therapy—as a third to one half do—it is
reasonable to continue treatment. If patients do not
have symptoms and the hormone level seems stable
with thyroid peroxidase antibodies present, the risk of
progression to overt hypothyroidism is a little less than
5% per year1 and so a yearly surveillance strategy for
thyroid stimulating hormone level is satisfactory. If
thyroid peroxidase antibodies are absent, then surveil-
lance of thyroid stimulating hormone levels every
three years is the current recommendation,8 with the
risk of progression to overt hypothyroidism being
around 2% per year. The exception to the above is in
pregnancy, or in someone trying to conceive, when
mild hypothyroidism should always be treated.
Patients with symptoms of hypothyroidism but normal
thyroid stimulating hormone levels
Although a normal level of thyroid stimulating hor-
mone excludes primary thyroid failure, if the result of a
serum free thyroxine assay is not available then
secondary hypothyroidism from pituitary or hypotha-
lamic disease could be present. This is almost always
associated with other hormonal deficiencies and result-
ingclinical clues (forexample, lowgonadotrophin levels
Box 1 Important causes of hypothyroidism
Autoimmune thyroiditis—Hashimoto’s thyroiditis, atrophic autoimmune thyroiditis
Iatrogenic—thyroidectomy, radioiodine therapy
Thyroiditis—subacute thyroiditis (also known as De Quervain’s thyroiditis), silent
thyroiditis, postpartum thyroiditis
Iodine deficiency
Drugs—carbimazole, methimazole, propylthiouracil, iodine, amiodarone, lithium,
interferons, thalidomide, sunitinib, rifampicin
Congenital hypothyroidism—thyroid aplasia or hypoplasia, defective biosynthesis of
thyroid hormones
Disorders of the pituitary or hypothalamus (secondary hypothyroidism)
Raised thyroid stimulating hormone levels
Thyroid stimulating hormone
level >10 mU/l with or without
low free serum thyroxine
Thyroid stimulating hormone
level 5-10 mU/l with
low free serum thyroxine
Thyroid stimulating hormone
level 5-10 mU/l with
normal free serum thyroxine
Symptoms of hypothyroidism
NoYes
Check status of thyroid peroxidase antibody
Positive result Negative result
Yes No
Treat with thyroxine
life long
Consider alternative
diagnoses
Recheck thyroid
stimulating
hormone
level annually
Recheck thyroid
stimulating
hormone level
every three years
3-6 months trial of thyroxine
Symptoms resolved?
Algorithm for pragmatic management of primary hypothyroidism in non-pregnant adults
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in a postmenopausal woman, amenorrhoea, galactor-
rhoea, erectile dysfunction). Owing to the possibility of
secondary adrenal failure, a full evaluation of pituitary
function is important before starting levothyroxine in
secondary hypothyroidism. A small but carefully done
clinical trial has shown that people with symptoms of
hypothyroidismbut anormal serumthyroid stimulating
hormone level do not get any improvement in their
symptoms with levothyroxine therapy.15
How to treat hypothyroidism?
Levothyroxine is the treatment of choice for
hypothyroidism.8Although levothyroxine is commonly
titrated upwards from a starting dose of 25-50 μg daily, a
randomised controlled trial has shown that this
approach is not necessary for most patients and is likely
to be wasteful of resources.16 So for most patients a full
replacement dose of levothyroxine should be started.
The exceptions to this are patients aged more than
60 years or those with ischaemic heart disease. The
requirement for levothyroxine depends on lean body
mass, and a daily dose of 1.6 μg/kg body weight will
render most patients euthyroid.17 This dose equates to
100μgdaily for theaverage sizedwoman(60kg)and125
μgdaily for theaverage sizedman (75kg).Whengivinga
trial of levothyroxine therapy for subclinical hypothy-
roidism, it is worth starting with close to a full
replacement dose (75 or 100 μg daily), on the basis that
it would be difficult to be sure if the symptomsmight not
becausedbyhypothyroidism,until a therapeuticdoseof
levothyroxine has been tried.
How to monitor levothyroxine replacement
Measurement of serum thyroid stimulating hormone is
the cornerstone of monitoring levothyroxine replace-
ment, the exception being people with pituitary
disease. In longstanding untreated hypothyroidism
there is pituitary thyrotrophhyperplasia, so the level of
thyroid stimulating hormone commonly takes three to
six months to fall into the reference range, even with
full dose initial replacement therapy. After starting
levothyroxine, thyroid stimulating hormone and free
thyroxine levels should be measured at eight to
12 weeks and adjustments made to the dose accord-
ingly. Although measuring thyroid stimulating hor-
mone levels annually is sufficient for someone
receiving a stable dose of levothyroxine, certain
situations are predictably associated with a change in
levothyroxine requirement, particularly pregnancy,
but to a lesser degree oestrogen use and after large
changes in body weight.18 19 The dose of levothyroxine
tends to decrease with advancing age owing to
decreased clearance of thyroxine and a reduction in
lean body mass.20
What is the target level for thyroid stimulating hormone?
The aim of levothyroxine treatment is to make the
patient feel better, and the dose should be adjusted to
maintain the level of thyroid stimulating hormone
within the lowerhalf of the reference range,21 around0.4
to2.5mU/l. If thepatient feels perfectlywellwith a level
Box 2 Presenting features of hypothyroidism
 Exhaustion
 Somnolence
 Slow cognition
 Intolerance to cold
 Constipation
 Depression
 Weight gain
 Calf stiffness
 Menstrual disturbance
 Carpal tunnel syndrome
 Hearing impairment
 Dry, thin and pale skin
 Puffiness below the eyes
 Bradycardia
 Slow relaxing tendon reflexes
 Coarsening of facial features
 Pleural effusion
 Pericardial effusion
 Ascites
 Non-pitting oedema of lower leg
 Hyponatraemia
 Hypercholesterolaemia
 Impaired consciousness (myxoedema coma)
Box 3What to tell patients with newly diagnosed hypothyroidism
 Levothyroxine has a half life of seven days in the bloodstream and it will take a week or
more to start to feel better. Conversely, if one tablet is missed out, there will be no
noticeable effect
 If muscle weakness, stiffness, or cognitive defects are present thesemay take up to six
months to fully resolve
 Levothyroxine should be taken on an empty stomach to maximise absorption
 Treatment isgenerally life longandonlysmall changes in levothyroxinedosageare likely
over that time, as determined by yearly measurements of thyroid stimulating hormone
levels
 In the UK, patients with hypothyroidism are eligible for a medical exemption certificate
for prescription charges (FP92)
Box 4 Drugs affecting dosage of levothyroxine
Drugs preventing absorption of levothyroxine
 Calcium salts
 Ferrous sulphate
 Aluminium hydroxide
 Cholestyramine
Drugs increasing clearance of levothyroxine
 Phenytoin
 Carbamazepine
 Phenobarbitone
 Rifampicin
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in the upper half of the reference range, then adjustment
is unnecessary. If persistent fatigue, somnolence, or
subtle cognitiveproblems (forgetfulness, befuddlement)
exist then it is reasonable to increase the dose by 25 μg
daily, or on alternate days. Although an open label non-
randomised studyhas suggested that titrating thedoseof
levothyroxine upward (often leading to suppression of
thyroid stimulating hormone) is associated with
improvement in wellbeing,22 this was not confirmed
by a recent randomised control trial.23 A fully
suppressed serum thyroid stimulating hormone level
(<0.1mU/l) should always be avoided.9 A low level (0.1
to0.4mU/l)maybeacceptable inayoungerpersonwho
does not feel fully well while taking a smaller dose of
levothyroxine. Low thyroid stimulating hormone levels
in older people (>60 years) should trigger a small dose
reduction of 25 μg daily, or on alternate days. A meta-
analysis has shown that low levels of thyroid stimulating
hormone (0.1 to 0.4 mU/l) increase the risk of
osteoporosis in over 60s.24 In addition, a longitudinal
observational study has indicated that low thyroid
stimulating hormone levels may contribute to a three-
fold increased risk of atrial fibrillation.25
What are the challenges of levothyroxine replacement?
A persistently abnormal thyroid stimulating hormone level
Patient non-compliance (non-concordance) with
levothyroxine therapy can sometimes be a problem.
When levothyroxine is taken only on the day of
attendance for the blood test this typically results in a
chronically raised thyroid stimulating hormone level
but normal or raised free thyroxine levels. In many
cases reiterating that levothyroxine has a long half life
(box 3) is sufficient to persuade the patient to take the
tablets regularly, even if they do not feel different on
dayswhen thedose ismissed. Inmost people it is safe to
recommend that they take a double dose on the day
after amissed tablet (exceptions being active ischaemic
heart disease and atrial fibrillation). A small rando-
mised controlled crossover trial has shown that giving
levothyroxineweekly (seven times thedaily dose taken
once a week) is a safe regimen26 and can be used in
refractory cases.
Less commonly a persistently raised thyroid stimulat-
ing hormone level despite an apparently adequate dose
of levothyroxine can be caused by drugs (box 4) or by
malabsorption. It is worth excluding coeliac disease
(measuringendomysealor transglutaminaseantibodies)
and autoimmune gastritis (measuring parietal cell anti-
bodies) in this situation, as observational studies have
shown that the two autoimmune conditions coexistwith
autoimmunehypothyroidismmoreoften thanwouldbe
expected.2728 Rarely, interference to the laboratory
assayas a result ofheterophil antibodiesbeingpresent in
the patient can lead to artefacts.
Patient does not feel well despite well controlled thyroid
stimulating hormone level (0.1 to 2.5 mU/l)
Other diagnoses, both physical and psychological,
need to be considered, asmild abnormalities of thyroid
function are common and the problem that is making
the patient feel unwell might not have been treated. If
the patient clearly reports feeling worse while taking
levothyroxine, this should suggestAddison’s disease.29
Other autoimmune conditions, particularly pernicious
anaemia, may coexist with hypothyroidism and be the
dominant cause of non-specific symptoms. Peoplewith
sleep apnoea may also have non-specific symptoms
that are superficially similar to hypothyroidism
Box 5 Selected populations requiring screening for hypothyroidism
 Patients with Down’s syndrome and Turner’s syndrome
 Patients taking drugs such as amiodarone, lithium, thalidomide, interferons, sunitinib,
and rifampicin
 Patients who have received radioiodine treatment or neck radiotherapy
 Patients who have had subtotal thyroidectomy
 Patients with type 1 diabetes and autoimmune Addison’s disease
Tips for non-specialists
 It may take several months before symptoms of hypothyroidism are resolved after
biochemical correction of hypothyroidism
 If thyroid stimulating hormone level is persistently raised after an adequate dose of
levothyroxine, suspect poor compliance (concordance), the presence of drug
interference, or malabsorption (for example, undiagnosed coeliac disease)
 If a newdrug is started, thinkwhether thedrugwould interferewith thyroxineabsorption
or thyroid hormone action; ferrous and calcium salts are common culprits
 Monitoring replacement with serum thyroid stimulating hormone alone is adequate in
most patients with hypothyroidism; the important exception being those with pituitary
or hypothalamic disease
 Consider referring to a specialist if symptoms do not improve or worsen after treatment
with levothyroxine, if serum thyroid stimulating hormone level remains persistently
raised while the patient is receiving a full dose of thyroxine, if other morbidity or
complications exist (such as active and unstable ischaemic heart disease), or in
pregnancy
A patient’s perspective
At the age of 40 I started feeling tired and was finding it
difficult to concentrate in a new job. At first I put it down to
pressures at work, but after sixmonths I was feeling quite
miserable. I found that I was coming home fromwork and
needed to take a nap before I could face an evening out. It
was increasingly difficult even towalk the 100muphill to
my house, needing to stop several times. I wasn’t out of
breath, it was just that my muscles ached too much to
walk. I was also always feeling cold.
However, it still tookme a full ninemonths before I visited
my doctor, who found out after a blood test that I had an
underactive thyroid gland and prescribed me
levothyroxine. The doctor was surprised that I was still
managing to function as my results were so extreme.
Within a few days of taking levothyroxine, I was feeling so
much better. It was unbelievable!
I remained well for the next 11 years, until I started to feel
extremely tired again, and this time I was losing weight. I
was diagnosed with type 1 diabetes and am beginning to
feel better again on insulin.
Tricia Condliffe, Exeter
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(tiredness, weight gain, poor concentration), and these
may have triggered testing of thyroid function.
If the thyroid stimulating hormone level is above
1.5 mU/l, a small dosage increment of 25 μg on
alternate days should be considered or a change to
nocturnal dosing, which may give a subtle increase in
absorption.30 If attempting to refine levothyroxine
dosages to achieve wellbeing, in our experience it is
worth recommending that the patient keeps to one
particular brand of levothyroxine to avoid small
differences between formulations that might cause a
change in symptoms.
Treating hypothyroidism in older patients and those
with ischaemic heart disease
Because people with longstanding hypothyroidism
may have bradycardia, which canmask substantial but
asymptomatic coronary artery disease,31 levothyrox-
ine should be replaced cautiously in older patients
(>60 years) or those with known ischaemic heart
disease. Particular attention is required in those with
profound and longstanding hypothyroidism (thyroid
stimulating hormone level >50 mU/l). In these
instances, or in someone with active angina pectoris
or recent acute coronary syndrome, the starting dose of
levothyroxine should be 12.5 or 25 μg daily, which
should then be increased every three to six weeks until
euthyroidism is achieved.
Hypothyroidism in pregnancy
Maternal hypothyroidism in pregnancy is associated
with adverse obstetric outcomes and long term
developmental sequelae. Referral to a specialist is
necessary. The management of hypothyroidism in
pregnancy has been discussed in detail in a recent
review.32
Current controversies
Who should be screened for hypothyroidism?
Routine population screening for thyroid disease is
controversial. A recent systemic review found insuffi-
cient evidence to recommend routine screening of
thyroid disease in the general adult population.33 UK
guidelines for the use of thyroid function tests,
however, recommend that specific groups of people
at high risk of developing hypothyroidism should be
offered annual screening (box 5).8
Should combined triiodothyronine with levothyroxine be
used?
Several studies have examined whether combination
therapy of primary hypothyroidism with triiodothy-
ronine and levothyroxine might be helpful. A recent
prospective study has, however, shown that normal
triiodothyronine levels could be achieved with
levothyroxine treatment alone in patients after total
thyroidectomy, wi thout the need to take
triiodothyronine.34 A meta-analysis of 11 randomised
controlled trials with more than 1000 participants has
shown no obvious benefit from combined triiodothy-
ronine and levothyroxine therapy.35 A major obstacle
to evaluation of such combined therapies is that no
currently available formulation contains levothyrox-
ine and triiodothyronine with the relative quantities
and release kinetics of the human thyroid gland.
How useful is porcine thyroid extract?
Porcine thyroid extract (common brand name Armour
thyroid; Forest Pharmaceuticals, USA) has never been
compared with levothyroxine treatment in a rando-
mised study. It is substantially more expensive than
levothyroxine and of no proved additional benefit.
Additional educational resources
Resources for healthcare professionals
Roberts CGP, Landenson PW. Hypothyroidism. Lancet 2004:363:793-803—An indepth
review on the pathogenesis and management of hypothyroidism
Thyroid disease manager (www.thyroidmanager.org/)—An online textbook that includes a
comprehensive chapter with up to date references on hypothyroidism
UK guidelines for the use of thyroid function tests (www.british-thyroid-association.org/
TFT_guideline_final_version_July_2006.pdf)—Guidelines on thyroid function tests, which
include a separate chapter on the investigations and treatment of hypothyroidism
Resources for patients
British Thyroid Foundation (www.btf-thyroid.org/)—Provides general information about
different thyroid disorders, patient information leaflets, local patient informationmeetings,
and telephone support
British Thyroid Association (www.british-thyroid-association.org/patient_info.htm)—Has a
separate section for information for patients, providing information on various thyroid
disorders
American Thyroid Association (www.thyroid.org/patients/patients.html)—Has a separate
section for patients, providing patient education brochures, frequently asked questions,
recommended list of books for patients and families, update on current thyroid research,
and links to other support organisations
HormoneFoundation (www.hormone.org/thyroid/)—Offers informationondifferent thyroid
andendocrinedisorders,with fact sheets, brochures, patient guides, andup todatepatient
information articles
Unanswered questions
Whydosomepatientswithhypothyroidismcontinue to feelunwell despite takingadequate
doses of levothyroxine?
Would a combination of levothyroxinewith slow release formulation of triidothyroninehave
advantages over levothyroxine therapy alone?
Is the vascular risk associatedwith subclinical hypothyroidismameliorated by early thyroid
hormone replacement?
Are there differences in long term outcome from treating adults with hypothyroidism to
different target ranges for serum thyroid stimulating hormone?
Current ongoing clinical trials
Evening versus morning administration of levothyroxine (Medical Centre Rijnmond-Zuid,
Netherlands)
Levothyroxine replacement in pregnant women with mild (subclinical) hypothyroidism
(University of Cardiff, UK, and National Institute of Child Health and Human Development,
USA)
Thyroid hormonedose adjustment in hypothyroid pregnant women (BrighamandWomen’s
Hospital, USA)
Generic versus name brand levothyroxine (Children’s Hospital Boston, USA)
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When should general practitioners refer?
Most patients with hypothyroidism can be managed
successfully in primary care.Referral should, however,
be considered in hypothyroid patients whose symp-
toms do not respond or worsen after treatment with
levothyroxine; the serum thyroid stimulatinghormone
level is persistently raised while taking the full dose of
levothyroxine; or if other morbidity or complications
exist (for example, active and unstable ischaemic heart
disease). Pregnant women with hypothyroidism
should also be referred.
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SUMMARY POINTS
Inadultswithnewly diagnosedhypothyroidismwhoareunder 60andwithout ischaemic heart
disease it is safe and efficient to start on a full replacement dose of levothyroxine
Levothyroxine replacement dose is related to body mass; a daily dose of about 1.6 μg
levothyroxine/kg body mass is adequate replacement for most adults (equivalent to 100 μg
daily or 125 μg daily for an average size woman or man, respectively)
Elderly people and those with ischaemic heart disease should start on a small dose of
levothyroxine, and the dose increment should be gradual
Current evidence does not support a clinical benefit from the use of a combination of
levothyroxine and liothyronine (triiodothyronine) over levothyroxine alone in the treatment of
hypothyroidism
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